Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas

Figure S1 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas

<p>Supplementary Figure 1: T cell responses in A2.DR1 and DR4 mice after peptide vaccination with potential shared neoepitopes. A. Predicted binding affinity for selected amino acid alterations for HLA-A*0201 determined by NetMHC 4.0. B, C. Quantification of IFN-Î³ ELISpot using cells isolated...

Saved in:

書目詳細資料
主要作者:	Michael Kilian (16697663) (author)
其他作者:	Mirco Friedrich (3721555) (author), Khwab Sanghvi (16697666) (author), Edward Green (3822586) (author), Stefan Pusch (14934437) (author), Daisuke Kawauchi (15115187) (author), Martin Löwer (133159) (author), Jana K. Sonner (16697669) (author), Christopher Krämer (16697672) (author), Julia Zaman (16697675) (author), Stefanie Jung (554730) (author), Michael O. Breckwoldt (16697678) (author), Gerald Willimsky (16697681) (author), Stefan B. Eichmüller (16697684) (author), Andreas von Deimling (15037904) (author), Wolfgang Wick (15018168) (author), Felix Sahm (15097382) (author), Michael Platten (15018165) (author), Lukas Bunse (16697687) (author)
出版:	2025
主題:	Cancer Immuno-oncology CNS Cancers Gliomas, Glioblastomas Immunology Tumor antigens/neoantigens Immunotherapy Cellular immunotherapy
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Figure S2 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
由: Michael Kilian (16697663)
出版: (2025)

Figure S3 from T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
由: Michael Kilian (16697663)
出版: (2025)

Supplementary Table S1 from Neoantigen Targetability in Progressive Advanced Melanoma
由: Jitske van den Bulk (17142147)
出版: (2025)

Supplementary Table S2 from Neoantigen Targetability in Progressive Advanced Melanoma
由: Jitske van den Bulk (17142147)
出版: (2025)

Supplementary Table S3 from Neoantigen Targetability in Progressive Advanced Melanoma
由: Jitske van den Bulk (17142147)
出版: (2025)

Supplementary Table S4 from Neoantigen Targetability in Progressive Advanced Melanoma
由: Jitske van den Bulk (17142147)
出版: (2025)

Supplementary Table S5 from Neoantigen Targetability in Progressive Advanced Melanoma
由: Jitske van den Bulk (17142147)
出版: (2025)

Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
由: Maria Lozano-Rabella (15056515)
出版: (2025)

Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
由: Maria Lozano-Rabella (15056515)
出版: (2025)

Supplementary Data S3 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
由: Maria Lozano-Rabella (15056515)
出版: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
由: Isha Mondal (16721699)
出版: (2025)

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
由: Joseph Toker (15399882)
出版: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
由: Joseph Toker (15399882)
出版: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
由: Joseph Toker (15399882)
出版: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
由: Joseph Toker (15399882)
出版: (2025)

Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
由: Joseph Toker (15399882)
出版: (2025)

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
由: Joseph Toker (15399882)
出版: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
由: Joseph Toker (15399882)
出版: (2025)

Supplementary Data 1 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
由: Francesca Orzan (15055579)
出版: (2025)

Supplementary Data 2 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
由: Francesca Orzan (15055579)
出版: (2025)

Supplementary Data 3 from Liquid Biopsy of Cerebrospinal Fluid Enables Selective Profiling of Glioma Molecular Subtypes at First Clinical Presentation
由: Francesca Orzan (15055579)
出版: (2025)

Supplementary Table S1 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
由: Mengjie Zhao (14845174)
出版: (2025)

Supplementary Table S2 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
由: Mengjie Zhao (14845174)
出版: (2025)

Supplementary Table S4 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
由: Mengjie Zhao (14845174)
出版: (2025)

Supplementary Table S5 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
由: Mengjie Zhao (14845174)
出版: (2025)

Supplementary Table S8 from PGC1α Degradation Suppresses Mitochondrial Biogenesis to Confer Radiation Resistance in Glioma
由: Mengjie Zhao (14845174)
出版: (2025)

Supplementary video from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
由: Min Wu (14962986)
出版: (2025)

Table S1 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
由: Min Wu (14962986)
出版: (2025)

Table S2 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
由: Min Wu (14962986)
出版: (2025)

Table S3 from Phagocytosis of Glioma Cells Enhances the Immunosuppressive Phenotype of Bone Marrow–Derived Macrophages
由: Min Wu (14962986)
出版: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
由: Sied Kebir (15048732)
出版: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
由: Sied Kebir (15048732)
出版: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
由: Sied Kebir (15048732)
出版: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
由: Sied Kebir (15048732)
出版: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
由: Sied Kebir (15048732)
出版: (2025)

Supplementary Figures from Distinct Cell Adhesion Signature Defines Glioblastoma Myeloid-Derived Suppressor Cell Subsets
由: Defne Bayik (14961098)
出版: (2025)

Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
由: Qingsheng Xu (17078830)
出版: (2025)

Supplementary Table S3 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma
由: Qingsheng Xu (17078830)
出版: (2025)

Figures 1 from Preclinical Efficacy of LP-184, a Tumor Site Activated Synthetic Lethal Therapeutic, in Glioblastoma
由: Bachchu Lal (17141949)
出版: (2025)

Graphical abstract from Single-Cell Spatial Analysis Identifies Regulators of Brain Tumor–Initiating Cells
由: Reza Mirzaei (15306062)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_63peo3qkd3std2hpbe6tavemj0